Insider Activity Update: John Roush Executes Options Exercise, Resulting In $433K At LeMaitre Vascular

Disclosed in a recent SEC filing on August 13, Roush, Board Member at LeMaitre Vascular (NASDAQ:LMAT), made a noteworthy transaction involving the exercise of company stock options.

What Happened: Disclosed in a Form 4 filing on Wednesday with the U.S. Securities and Exchange Commission, Roush, Board Member at LeMaitre Vascular, executed a strategic derivative sale. This involved exercising stock options for 7,500 shares of LMAT, resulting in a transaction value of $433,050.

During Wednesday's morning session, LeMaitre Vascular shares up by 0.69%, currently priced at $95.03. Considering the current price, Roush's 7,500 shares have a total value of $433,050.

About LeMaitre Vascular

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.

Breaking Down LeMaitre Vascular's Financial Performance

Revenue Growth: LeMaitre Vascular displayed positive results in 3 months. As of 30 June, 2025, the company achieved a solid revenue growth rate of approximately 15.01%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.

Interpreting Earnings Metrics:

• Gross Margin: The company maintains a high gross margin of 70.02%, indicating strong cost management and profitability compared to its peers.

• Earnings per Share (EPS): LeMaitre Vascular's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.61.

Debt Management: LeMaitre Vascular's debt-to-equity ratio stands notably higher than the industry average, reaching 0.51. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.

Financial Valuation Breakdown:

• Price to Earnings (P/E) Ratio: The P/E ratio of 46.04 is lower than the industry average, implying a discounted valuation for LeMaitre Vascular's stock.

• Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 9.21 as compared to the industry average, the stock might be considered overvalued based on sales performance.

• EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): A high EV/EBITDA ratio of 27.15 positions the company as being more valued compared to industry benchmarks.

Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.

Illuminating the Importance of Insider Transactions

It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.

In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.

Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.

Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.

Navigating the World of Insider Transaction Codes

Taking a closer look at transactions, investors often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.

Check Out The Full List Of LeMaitre Vascular's Insider Trades.

Insider Buying Alert: Profit from C-Suite Moves

Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. Click here for access.

This article was generated by Benzinga's automated content engine and reviewed by an editor.